TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03909802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-and family management of diabetic foot ulcers programs
Description: The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT02271750

Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: for spinal fluid

Intervention type: PROCEDURE
Intervention: lumbar puncture
Description: for spinal fluid
Study: NCT06130163

Intervention type: PROCEDURE
Intervention: endoscopic retrograde cholangiopancreatography
Description: endoscopical clearance of the common bile duct

Intervention type: PROCEDURE
Intervention: endoscopic retrograde cholangiopancreatography
Description: endoscopical clearance of the common bile duct
Study: NCT01484795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BILEVEL (Respironics)
Description: Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuos positive airway pressure (Respironics)
Description: CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
Study: NCT04318756

Intervention type: BEHAVIORAL
Intervention: Translation and cultural adaptation go the cancer worry scale
Description: To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.

Intervention type: BEHAVIORAL
Intervention: Translation and cultural adaptation go the cancer worry scale
Description: To develop and validate the Italian version of Cancer worry scale using high risk subjects for familiarity/genetic predisposition and patients with premalignant lesions.
Study: NCT03549234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae (single injection)
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral (single injection)
Description: Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
Study: NCT00406471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (Lucentis)
Description: 500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
Study: NCT00962585

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~* S-equol 10 mg BID (20 mg total daily dose)~* S-equol 50 mg BID (100 mg total daily dose)~* S-equol 150 mg BID (300 mg total daily dose)
Study: NCT02323035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headgear
Description: Investigative Headgear with CPAP Mask.
Study: NCT01916499

Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; coronary artery status

Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; coronary artery status

Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; ventricular function and morphology

Intervention type: OTHER
Intervention: 3 tesla magnetic resonance imaging findings; ventricular function and morphology
Study: NCT04166929

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo SCT with NK cells
Description: Patients in this arm receive haplo-SCT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haplo SCT
Description: Patients in this arm receive a standard haplo-SCT. All administerd therapies are the same as in other arm, except for the NK cell boost..
Study: NCT03880318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Joint Preserving Surgery in spasmodic flat foot
Description: extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
Study: NCT00840996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
Study: NCT02248961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Cozaar® (Losartan), manufactured by MERCK SHARP \& DOHME B.V., Netherlands, tablets 50/100 mg
Study: NCT00763399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics (antibiophilus(Lactobacillus casei), bio-three)
Description: probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10\^8CFU/day
Study: NCT01520389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: MM-151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151
Description: MM-151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-151 + irinotecan
Description: MM-151 + irinotecan
Study: NCT02858765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of white polychromatic light for 2h30 at different times of day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of white polychromatic light for 2h30 at different times of day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of white polychromatic light for 2h30 at different times of day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of white polychromatic light for 2h30 at different times of day
Study: NCT00852137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (ingenol mebutate) Gel, 0.05%
Description: PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel once daily for 2 consecutive days
Study: NCT01900054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets will be taken orally twice a day
Study: NCT00517465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1511
Description: Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1511
Description: Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1511
Description: Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
Study: NCT04013958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketamine
Description: IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM Ketamine
Description: IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
Study: NCT01784315

Intervention type: DRUG
Intervention: Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax
Description: 4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.

Intervention type: DRUG
Intervention: Chloroquine and Primaquine
Description: Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
Study: NCT03518528

Intervention type: DRUG
Intervention: Estradiol 2 MG
Description: Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks

Intervention type: DRUG
Intervention: Estradiol 100 µg
Description: transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
Study: NCT02746575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol
Study: NCT00674635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK3152314A
Description: Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT04757467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy neuro-rehabilitation
Description: Treatment interventions which will be used for this group Passive range of movement exercises. Therapeutic positioning of the lower limb. Strengthening exercise for the lower limb. Over-ground gait training 5 times a week for 4 weeks. First week= 30 min exercise Second week= 1hour exercise Third week= 1hour and 30 min exercise Fourth week= 2 hours exercise All the treatment protocols will be applied to the patient for 5 times a week for consecutive 4 weeks. Interventions will be performed in the clinic and through home-based exercises using patient education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetition-CIMT
Description: In this group of patients, the CIMT technique will be used for treatment. Following tasks will be performed by the patient, the unaffected limb will be constrained using a tight knee brace for about3 hr.~* Sit-to-Stand~* Forward and Backward stepping~* Stair Climbing and Descending (only the first stair will be used)~* Side-to-Side stepping with the affected limb~Each task will be performed 10 times per session in the first week and 2 sessions a day. In the second week, each task will be performed 20 times per session for 2 sessions a day. In the third week, each task will be performed 30 times per session for 2 sessions a day.In the fourth week, each task will be performed 40 times per session for 2 sessions a day. The session will be held 5 days in a week for the period of consecutive 4 weeks. Total of 1000 repetitions of the above mentions tasks will be performed in 4 weeks' study time by every participant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hour-CIMT
Description: A task that performed by the participants in this group will be the same as performed by the rep-CIMT group. The unaffected limb will be in constrained for 3 hours. (15) Sessions will be held 5 days in the week for a period of consecutive 4 weeks.
Study: NCT02629068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PURPOSE
Description: The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together
Study: NCT03917160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMS device
Description: EMS treatment will be performed
Study: NCT00153946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone
Description: 30mg/20mL vial, twice per day, not longer than two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edaravone
Description: 30mg/20mL vial, twice per day, not longer than two weeks
Study: NCT01242176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 XX (Trial Formulation 2)
Description: one single dose tablet in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 (Final Formulation)
Description: one single film-coated tablet in the morning
Study: NCT01296490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
Study: NCT01679613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: low dose oral administration
Study: NCT02612896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mass drug administration, praziquantel 10mg/kg
Description: see previous, in elimination study arm only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: in all study arms, using village meetings, posters, pamphlets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: in all study arms, using village meetings, posters, pamphlets.
Study: NCT03622385

Intervention type: OTHER
Intervention: DNA Methylation
Description: No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.

Intervention type: OTHER
Intervention: DNA Methylation
Description: No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
Study: NCT01886963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY - Unblinded use of SPY Elite
Description: Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Blinded use of SPY Elite
Description: Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
Study: NCT02184663

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without APA program
Description: Control Arm : chemotherapy alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APA program
Description: Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
Study: NCT04529720

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Pertagen (aP BioNet)
Description: Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Boostagen (TdaP BioNet)
Description: Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TdaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.

Intervention type: BIOLOGICAL
Intervention: Biological/Vaccine: Adacel
Description: Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each participant will be received one intramuscular injection in the non-dominant deltoid region.
Study: NCT02608489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol (Diquas)
Description: Diquafosol group used diquafosol 6 times a day during study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate (Hyalein)
Description: Hyaluronate group used sodium hyaluronate 6 times a day during study period.
Study: NCT03758820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavorial Cognitive Therapy (BCT)
Description: Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises.
Study: NCT03816241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frame
Description: Vignette is framed in a way that nudges participant to leave a legacy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norms
Description: Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
Study: NCT01026909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aristospan 20mg
Description: Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
Study: NCT03926065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Vegetables Served in 100% Portion Size
Description: Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain Vegetables Served in 200% Portion Size
Description: Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Vegetables Served in 100% Portion Size
Description: Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Vegetables Served in 200% Portion Size
Description: Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
Study: NCT01984424

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin was supplied as over-encapsulated 20 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin was supplied as over-encapsulated 20 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Atorvastatin
Description: Placebo matching to atorvastatin supplied as over-encapsulated tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to Atorvastatin
Description: Placebo matching to atorvastatin supplied as over-encapsulated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Ezetimibe
Description: Placebo matching to Ezetimibe supplied as over-encapsulated tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab supplied as single-use prefilled autoinjector/pen(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab supplied as single-use prefilled autoinjector/pen(s)
Study: NCT04105972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: FDC tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Mono tablet for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Mono tablet for oral administration.